Trial reportAnnals of surgical oncology2026
Minimizing Early-Onset Lymphedema Following Groin Dissection in Metastatic Melanoma.
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Rethinking Lymphedema Prophylaxis After Groin Dissection for Melanoma.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLymphedema is a common and burdensome complication after groin dissection for metastatic melanoma. This study evaluated whether a 6-month program of compression garments combined with simple lymphatic drainage (CG-SLD) reduces the rate of lymphedema presentation compared with standard care (SC). PATIENTS AND
methodsParticipants were randomized 1:1 to SC or CG-SLD for 6 months postoperatively. Lymphedema was assessed preoperatively and every 3 months for 24 months using interlimb volume difference and bioimpedance spectroscopy. The primary end point was the incidence of lymphedema at 24 months. Secondary outcomes included time to lymphedema development, lymphedema severity, and quality of life (QoL). The study was powered to detect a reduction in 24 month incidence from 45 to 18% (α = 0.05, 80% power), requiring 88 participants.
resultsA total of 38 participants were randomized (SC n = 20; CG-SLD n = 18), below the planned sample size. At 24 months, lymphedema incidence was numerically higher but nonsignificant for SC compared with CG-SLD; 55% (31.5-76.9) versus 38.9% (17.3-64.3). All new lymphedema events occurred within 12 months. Early lymphedema severity at 3 months favored CG-SLD; however, no persistent between-group differences were observed at later time points. There was no statistical evidence to support a difference in QoL scores at any time point.
conclusionsCG-SLD did not reduce lymphedema incidence compared with SC at 24 months. Although early reductions in lymphedema incidence and severity were observed for CG-SLD, these were not maintained beyond 6 months when interventions ceased. The study was underpowered, and larger trials are required to determine whether early prophylactic strategies provide durable benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.